Home > Products and Services > Image Galleries > East and North Asia Gallery

ScinoPharm completed its API contract manufacturing plant in 2001 and an adjacent biotechnology plant in 2004.
ScinoPharm completed its API contract manufacturing plant in 2001 and an adjacent biotechnology plant in 2004.
 Part of the large-scale API production facilities at ScinoPharm.
Part of the large-scale API production facilities at ScinoPharm.
 ScinoPharm was first set up in the US in 1994 as a bulk material subcontractor to major pharmaceutical firms.
ScinoPharm was first set up in the US in 1994 as a bulk material subcontractor to major pharmaceutical firms.
As the global pharmaceutical industry becomes more diverse, many international drug makers are subcontracting the production of bulk pharmaceuticals to other companies on an outsourcing basis.
As the global pharmaceutical industry becomes more diverse, many international drug makers are subcontracting the production of bulk pharmaceuticals to other companies on an outsourcing basis.
 The plant has seven operating areas designed to handle any scale of production from kilo-lab scale 1kg up to a commercial scale of 100kg.
The plant has seven operating areas designed to handle any scale of production from kilo-lab scale 1kg up to a commercial scale of 100kg.
 The plant produces a range of products, including Paclitaxol, Mestranol, Riluzole, Flumenazil and Lisinopril.
The plant produces a range of products, including Paclitaxol, Mestranol, Riluzole, Flumenazil and Lisinopril.
The administration building, technology building, waste water processing plant and main factory for the first stage production lines of the 6.6ha facility were completed in the first phase of the project.
The administration building, technology building, waste water processing plant and main factory for the first stage production lines of the 6.6ha facility were completed in the first phase of the project.
 The plant complex in December 1999.
The plant complex in December 1999.
 Location of Iksan plant
Location of Iksan plant
The facility was expanded further in 2001–2002.
The facility was expanded further in 2001–2002.
 The structure of the Factive molecule.
The structure of the Factive molecule.
 Factive tablet and packets.
Factive tablet and packets.
A map of Odawara.
A map of Odawara.
 Nippon Shinyaku Corporation's Plant in Odawara of Kanagawa, Japan.
Nippon Shinyaku Corporation's Plant in Odawara of Kanagawa, Japan.
 The pie diagram shows the level of spending on health in Japan, as a percentage of GDP.
The pie diagram shows the level of spending on health in Japan, as a percentage of GDP.
The Glaxo Wellcome plant produces new anti infectives drugs including a treatment for <BR>hepatitis B.
The Glaxo Wellcome plant produces new anti infectives drugs including a treatment for
hepatitis B.
 The Suzhou plant will be completed in 2001.
The Suzhou plant will be completed in 2001.
 Glaxo Welcome's new Facility in Suzhou of Jiangsu, China.
Glaxo Welcome's new Facility in Suzhou of Jiangsu, China.
Pie chart showing health expenditure in China.
Pie chart showing health expenditure in China.
 Nycomed Amersham plc's New Facility in Shanghai, China.
Nycomed Amersham plc's New Facility in Shanghai, China.
 Chart showing health expenditure in proportion to GDP.
Chart showing health expenditure in proportion to GDP.
The Pharmadule method involves the construction of individual modules like this which are then shipped out to the facility site.
The Pharmadule method involves the construction of individual modules like this which are then shipped out to the facility site.
 The modular construction allows for easy expansion. This is important as Nycomed Amersham are likely to want to expand if the Chinese joint venture is as successful as is hoped.
The modular construction allows for easy expansion. This is important as Nycomed Amersham are likely to want to expand if the Chinese joint venture is as successful as is hoped.
 The construction of the modules in Sweden allows them to be tested before shipment.
The construction of the modules in Sweden allows them to be tested before shipment.
MRI brainscan image.
MRI brainscan image.
 Health Expenditure as a percentage of GDP in Japan.
Health Expenditure as a percentage of GDP in Japan.
 Location of Sumitomo Pharmaceuticals plant in Ibaraki.
Location of Sumitomo Pharmaceuticals plant in Ibaraki.
Location of the Sumitomo Pharmaceuticals Ehime Bio facilities.
Location of the Sumitomo Pharmaceuticals Ehime Bio facilities.
 Astra Zeneca's Facility in Wuxi near Shanghai of Jiangsu China.
Astra Zeneca's Facility in Wuxi near Shanghai of Jiangsu China.
 Chart showing health expenditure as a percentage of GDP.
Chart showing health expenditure as a percentage of GDP.
The city of Shanghai is a good location for AstraZeneca as its economy is growing at fantastic pace.
The city of Shanghai is a good location for AstraZeneca as its economy is growing at fantastic pace.
 The new packaging line at the Wuxi plant will allow 40 million more units per year to be packaged.
The new packaging line at the Wuxi plant will allow 40 million more units per year to be packaged.
 An overview of the Daiichi facilities.
An overview of the Daiichi facilities.
Daiichi Pharmaceuticals' New Facility in Beijing, China.
Daiichi Pharmaceuticals' New Facility in Beijing, China.
 Health expenditure as a percentage of GDP in China.
Health expenditure as a percentage of GDP in China.
 Boehringer Ingelheim's new pharmaceutical manufacturing facility in Shanghai was opened in March 2002.
Boehringer Ingelheim's new pharmaceutical manufacturing facility in Shanghai was opened in March 2002.
Tablets manufactured in Shanghai undergoing dissolution tests.
Tablets manufactured in Shanghai undergoing dissolution tests.
 Range of tablets manufactured in Shanghai.
Range of tablets manufactured in Shanghai.
 Boehringer's newly designed metered dose inhaler will be manufactured at the Shanghai plant.
Boehringer's newly designed metered dose inhaler will be manufactured at the Shanghai plant.
Boehringer Ingelheim will produce their most popular products at the Shanghai plant, aimed at the Chinese market.
Boehringer Ingelheim will produce their most popular products at the Shanghai plant, aimed at the Chinese market.
 The Utsunomiya plant will be crucial in establishing Chugai as one of the largest potential commercial suppliers of treatments such as MRA, a humanised anti-IL-6 receptor monoclonal antibody (Atlizumab) indicated for rheumatoid arthritis.
The Utsunomiya plant will be crucial in establishing Chugai as one of the largest potential commercial suppliers of treatments such as MRA, a humanised anti-IL-6 receptor monoclonal antibody (Atlizumab) indicated for rheumatoid arthritis.
 Some of the process equipment supplied by Amersham Biosciences.
Some of the process equipment supplied by Amersham Biosciences.
Bioreactors installed at the new phase one facility.
Bioreactors installed at the new phase one facility.
 Granocyte, an important product for Chugai produced at the Usunomiya plant.
Granocyte, an important product for Chugai produced at the Usunomiya plant.
 A microscopic view of multiple myeloma, a condition the new MRA antibody drugs will be designed to treat.
A microscopic view of multiple myeloma, a condition the new MRA antibody drugs will be designed to treat.
A healthy red blood cell count. One of Chugai's products is erythropoietin, a hormone that regulates the quantity of red blood cells in the body.
A healthy red blood cell count. One of Chugai's products is erythropoietin, a hormone that regulates the quantity of red blood cells in the body.
 A researcher at Chugai Pharmaceutical working on new antibody technology.
A researcher at Chugai Pharmaceutical working on new antibody technology.
 An exterior view of the new facility.
An exterior view of the new facility.
An exterior view of the new NBP.
An exterior view of the new NBP.
 Some of the equipment installed in the manufacturing area.
Some of the equipment installed in the manufacturing area.
 A view of the administrative area of the NBP.
A view of the administrative area of the NBP.
Showing the exterior of the NBP.
Showing the exterior of the NBP.
 A group of natriuretic peptides, some of which may well form part of future therapies for Asubio.
A group of natriuretic peptides, some of which may well form part of future therapies for Asubio.
 Location Map of Roche's Shanghai pharmaceuticals plant.
Location Map of Roche's Shanghai pharmaceuticals plant.
The niacinamide project was commissioned in the last half of 1999 at a cost of $30 million.
The niacinamide project was commissioned in the last half of 1999 at a cost of $30 million.
Production building and warehouse at the plant in the south western region of South Korea.
Production building and warehouse at the plant in the south western region of South Korea.
 The Chinese plant is part of a wider expansion plan of Lonza, which is seeing investment in manufacturing facilities in Switzerland, the USA and China.
The Chinese plant is part of a wider expansion plan of Lonza, which is seeing investment in manufacturing facilities in Switzerland, the USA and China.
Analytical lab for raw materials intermediates and final products.
Analytical lab for raw materials intermediates and final products.
 Location of Chitose: site of the world´s first human serum albumin plant.
Location of Chitose: site of the world´s first human serum albumin plant.
 A molecule of human serum albumin, the world's most-used intravenous protein.
A molecule of human serum albumin, the world's most-used intravenous protein.
Artist impression of the new Celltrion Biopharmaceutical Plant in Incheon, South Korea.
Artist impression of the new Celltrion Biopharmaceutical Plant in Incheon, South Korea.
 The plant includes four independent trains of bioreactors; each train comprises 20L, 100L, 500L, 2,500L inoculum seed reactors and a 12,500L production bioreactor.
The plant includes four independent trains of bioreactors; each train comprises 20L, 100L, 500L, 2,500L inoculum seed reactors and a 12,500L production bioreactor.
 The new facility will start production with therapeutic monoclonal antibodies as a custom manufacturing facility for third parties.
The new facility will start production with therapeutic monoclonal antibodies as a custom manufacturing facility for third parties.
The plant is to be used for the production of vaccines (particularly for AIDS and anthrax) and also for the production of therapeutic proteins.
The plant is to be used for the production of vaccines (particularly for AIDS and anthrax) and also for the production of therapeutic proteins.
 HIV budding.
HIV budding.
 Anthrax Bacillus.
Anthrax Bacillus.
Anthrax protection.
Anthrax protection.
 Anthrax toxins.
Anthrax toxins.
 One of the large bioreactors in the Celltrion facility.
One of the large bioreactors in the Celltrion facility.
The Celltrion building, which is soon to be expanded so that the facility will have a capacity of 230,000l.
The Celltrion building, which is soon to be expanded so that the facility will have a capacity of 230,000l.
 Work underway in the research section of the company.
Work underway in the research section of the company.
 Module for the new facility being hoisted into position.
Module for the new facility being hoisted into position.
The NovoPen 3 which will be produced at the new facility.
The NovoPen 3 which will be produced at the new facility.
 The NovoPen system uses extra fine needles.
The NovoPen system uses extra fine needles.
 Some of the pens use a disposable cartridge system and some are completely disposable.
Some of the pens use a disposable cartridge system and some are completely disposable.
The patient uses a dial on the pen to set the correct dosage of insulin to be administered.
The patient uses a dial on the pen to set the correct dosage of insulin to be administered.
 Insulin molecule peptide components.
Insulin molecule peptide components.
 The facility has state of the art equipment designed by the company for its own specific requirements.
The facility has state of the art equipment designed by the company for its own specific requirements.
The Unit Factory building in Takayama City on the Taiyo Pharmaceutical Industry campus.
The Unit Factory building in Takayama City on the Taiyo Pharmaceutical Industry campus.
 The company has moved into contract filling and packaging of pre-filled syringes with a big investment in a new manufacturing facility.
The company has moved into contract filling and packaging of pre-filled syringes with a big investment in a new manufacturing facility.
 Taiyo also manufactures generic antibiotics and vitamins.
Taiyo also manufactures generic antibiotics and vitamins.
The plant is in the Takayama Prefecture in Japan.
The plant is in the Takayama Prefecture in Japan.
 Cellcept as produced at the new plant (suspension form).
Cellcept as produced at the new plant (suspension form).
 The plant has high containment glove boxes.
The plant has high containment glove boxes.
Shanghai is one of the wonders of the modern industrial age it is a power house of Chinese manufacturing of all types.
Shanghai is one of the wonders of the modern industrial age it is a power house of Chinese manufacturing of all types.
 The molecular structure of Cellcept.
The molecular structure of Cellcept.
 Xeloda tablets are also produced at the new high containment plant.
Xeloda tablets are also produced at the new high containment plant.
The new vaccine needs only one dose to give excellent protection.
The new vaccine needs only one dose to give excellent protection.
 The danger areas for Japanese encephalitis cover a lot of the Far East.
The danger areas for Japanese encephalitis cover a lot of the Far East.
 A mosquito laying eggs in water.
A mosquito laying eggs in water.
A child suffering from the disease in an Indian medical centre.
A child suffering from the disease in an Indian medical centre.
 Paddy fields provide a perfect breeding ground for the disease vector.
Paddy fields provide a perfect breeding ground for the disease vector.
 The Mosquito that can spread the disease in exactly the same way as malaria.
The Mosquito that can spread the disease in exactly the same way as malaria.
Eskayef is based in Dhaka, Bangladesh.
Eskayef is based in Dhaka, Bangladesh.
 Dhaka is the industrial capital of Bangladesh and Eskayef has built the new plant in the Tongi industrial estate, on the outskirts of the city.
Dhaka is the industrial capital of Bangladesh and Eskayef has built the new plant in the Tongi industrial estate, on the outskirts of the city.
 Salbutamol is one of the company's most recent offerings, launched in 2006.
Salbutamol is one of the company's most recent offerings, launched in 2006.
Bird flu is a concern in Asia and Eskayef has recently released a preventative against the disease.
Bird flu is a concern in Asia and Eskayef has recently released a preventative against the disease.
 The company produces a wide variety of drugs for the domestic market but is now going to move into European markets.
The company produces a wide variety of drugs for the domestic market but is now going to move into European markets.
Copyright Notice: Copyright for all images on this web site is held by the individual companies providing material for the site. Click on the image concerned to be taken through to the project, containing information on the company involved.


client logon
Home
Industry Projects
Products & Services
Company A-Z
White Papers
Jobs & Careers
Press Releases
Advertise With Us
Events & Exhibitions
Newsletter
New On This Site
About Us
Atom FeedRSS Feed
What is RSS?